ChiCTR2600125898 版本V1.0 版本创建时间2026/06/01 16:27:04 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600125898 

最近更新日期:

Date of Last Refreshed on:

2026-06-01 16:25:13 

注册时间:

Date of Registration:

2026-06-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

用多项无创监测指标提前判断重症患者拔管失败风险的研究

Public title:

Using Multiple Non-invasive Monitoring Tools (EIT, Ultrasound, Heart Rate Variability) to Predict Breathing Tube Removal Failure in ICU Patients

注册题目简写:

English Acronym:

MULTI-EXFU

研究课题的正式科学名称:

多模态指标对撤机失败的预测价值探索:一项基于多元分析的前瞻性观察性研究

Scientific title:

Exploring the Predictive Value of Multimodal Parameters for Extubation Failure: A Prospective Observational Study with Multivariate Analysis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

梁国鹏 

研究负责人:

梁国鹏 

Applicant:

Guopeng Liang 

Study leader:

Guopeng Liang 

申请注册联系人电话:

Applicant telephone:

+86 28 8542 2114

研究负责人电话:

Study leader's telephone:

+86 28 8542 2114

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

Liangguopeng007@163.com

研究负责人电子邮件:

Study leader's E-mail:

liangguopeng007@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省成都市武侯区国学巷37号

研究负责人通讯地址:

四川省成都市武侯区国学巷37号

Applicant address:

37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province

Study leader's address:

37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

四川大学华西医院

Applicant's institution:

West China Hospital of Sichuan University

研究负责人所在单位:

四川大学华西医院

Affiliation of the Leader:

West China Hospital of Sichuan University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025年审(2852)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川大学华西医院生物医学伦理审查委员会

Name of the ethic committee:

Ethics Committee on Biomedical Research West China Hospital of Sichuan University

伦理委员会批准日期:

Date of approved by ethic committee:

2026-02-10 00:00:00

伦理委员会联系人:

李娜

Contact Name of the ethic committee:

Lina

伦理委员会联系地址:

四川省成都市武侯区国学巷37号

Contact Address of the ethic committee:

37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 28 85422654

伦理委员会联系人邮箱:

Contact email of the ethic committee:

188974152@qq.com

研究实施负责(组长)单位:

四川大学华西医院

Primary sponsor:

West China Hospital of Sichuan University

研究实施负责(组长)单位地址:

四川省成都市武侯区国学巷37号

Primary sponsor's address:

37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川省

市(区县):

Country:

China

Province:

Sichuan

City:

单位(医院):

四川大学华西医院

具体地址:

四川省成都市武侯区国学巷37号

Institution
hospital:

West China Hospital of Sichuan University

Address:

#37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-financed Programs

Target disease:

Respiratory failure

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

主要目的:系统评估并对比各单一多模态指标(包括 EIT、超声指标、CPF、HRV 及传统临床指标)对机械通气患者撤机失败的预测性能,明确其诊断价值。 次要目的: 预测方法探索:尝试性构建简约临床模型与 AI 模型,初步比较不同建模方法的潜力。 多元关系挖掘:通过相关性分析、亚组分析等方法,探讨指标间的内在关联与临床背景下的表现差异。 数据驱动发现:利用无监督聚类初步探索撤机失败的潜在生理表型。  

Objectives of Study:

Primary Objective: To systematically evaluate and compare the predictive performance of individual multimodal parameters — including electrical impedance tomography (EIT), ultrasound?based indices, cough peak flow (CPF), heart rate variability (HRV), and traditional clinical variables — for weaning failure in mechanically ventilated patients, and to clarify their diagnostic value. Secondary Objectives: Prediction methodology exploration – To preliminarily construct a parsimonious clinical model and an artificial intelligence (AI) model and to compare the potential of different modelling approaches. Multivariate relationship discovery – To investigate internal correlations among parameters and performance differences across clinical contexts using correlation analysis, subgroup analysis, and related methods. Data?driven phenotyping – To preliminarily explore potential physiological phenotypes of weaning failure using unsupervised clustering.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 年龄≥18 岁的成年患者 2. 接受有创机械通气治疗≥24 小时 3. 符合 SBT 筛查标准,主管医生已决定进行 SBT。 4. 患者或法定代理人签署知情同意书;

Inclusion criteria

1. Adult patients aged >=18 years 2. Receiving invasive mechanical ventilation for >=24 hours 3. Meet spontaneous breathing trial (SBT) screening criteria, with the attending physician having decided to perform SBT 4. Written informed consent obtained from the patient or legally authorized representative;

排除标准:

1. 存在影响 EIT 监测的技术因素(如胸部大面积烧伤、敷料、植入式除颤器) 2. 严重神经肌肉疾病,包括 C4 及以上脊髓损伤、重症肌无力、格林巴利综合症 3. 严重意识障碍 GCS 评分≤8 分且非药物可逆 4. 已行气管切开术 5. 计划拔管后 24 小时内转院或放弃积极治疗 6. 妊娠或哺乳期妇女 7. 终末期疾病(预期生存期<7 天)或接受纯粹姑息治疗 8. 存在严重影响 HRV 分析的心律失常(如持续房颤、频发室性早搏);

Exclusion criteria:

1. Technical factors precluding EIT monitoring (e.g., large-area chest burns, wound dressings, implantable cardioverter-defibrillator) 2. Severe neuromuscular diseases, including spinal cord injury at C4 level or above, myasthenia gravis, Guillain-Barré syndrome 3. Severe consciousness impairment with Glasgow Coma Scale (GCS) score <=8, not reversible by medication 4. Prior tracheostomy 5. Planned transfer to another hospital or withdrawal of active treatment within 24 hours after extubation 6. Pregnancy or breastfeeding 7. End-stage disease (expected survival <7 days) or receiving purely palliative care 8. Cardiac arrhythmias that significantly affect HRV analysis (e.g., persistent atrial fibrillation, frequent premature ventricular contractions);

研究实施时间:

Study execute time:

From 2026-02-01 00:00:00 To 2027-05-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-01 00:00:00 To 2027-05-01 00:00:00  

干预措施:

Interventions:

组别:

组别1:撤机成功队列 vs 组别2:撤机失败队列

样本量:

150

Group:

Extubation success group vs Extubation failure group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川省 

市(区县):

 

Country:

China 

Province:

Sichuan 

City:

 

单位(医院):

四川大学华西医院 

单位级别:

三级甲等 

Institution
hospital:

West China Hospital of Sichuan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

撤机失败发生率

指标类型:

主要指标

Outcome:

Incidence rate of weaning failure

Type:

Primary indicator

测量时间点:

拔管后第7天或转出ICU时

测量方法:

撤机失败定义为:满足以下任一项——①拔管后7天内再插管;②拔管后需紧急升级为无创通气/高流量氧疗;③SBT成功后24小时内未拔管(非临床原因)。通过临床记录判定。

Measure time point of outcome:

On the 7th day after extubation or when being transferred out of the ICU

Measure method:

Weaning failure was defined as meeting any of the following criteria: 1 re-intubation within 7 days of extubation; 2 emergency upgrade to non-invasive ventilation/high flow oxygen therapy after extubation; 3 non-extubation within 24 hours of successful extubation (for non-clinical reasons) . Judged by Clinical Records.

指标中文名:

EIT参数(GII, SDRVD, V-D difference 、Pendelluft, EELI)

指标类型:

次要指标

Outcome:

EIT parameters (GII, SDRVD, V-D difference 、Pendelluft, EELI)

Type:

Secondary indicator

测量时间点:

T1-SBT前30-60min;T2-SBT早期5-10min;T3-SBT结束前5-10min T4拔管后6h左右

测量方法:

1.全局不均一指数 (GII) :评估整个肺野内通气分布不均匀程度的量化 指标。测量:基于 EIT 像素点潮气阻抗变异的变异系数计算。值越高, 通气分布越不均。 2. 区域通气延迟标准差 (SDRVD) 定义:量化不同肺区域达到通气峰值时间 的一致性。计算各像素点达峰时间与全局平均达峰时间之差的标准差。 测量:通过 EIT 数据计算各区域通气达峰时间的标准差。 3.腹背侧通气差 (V-

Measure time point of outcome:

T1 - 30-60 minutes before SBT; T2 - Early stage of SBT, 5-10 minutes; T3 - 5-10 minutes before the e

Measure method:

1.Global Inhomogeneity Index (GII): A quantitative measure assessing the degree of uneven ventilation distribution across the entire lung field. Calculation: Determined by the coefficient of variation of tidal impedance variability at EIT pixel points; higher values indicate more pronounced ventilation heterogeneity. 2.Regional Ventilation Delay Standard Deviation (SDRVD): Measures the consistency in peak ventilation timing across different lung regions by calculating the standard deviation of

指标中文名:

HRV(SDNN 、RMSSD HF LF LF/HF TP )

指标类型:

次要指标

Outcome:

HRV(SDNN 、RMSSD HF LF LF/HF TP )

Type:

Secondary indicator

测量时间点:

T1-SBT前30-60min;T2-SBT早期5-10min;T3-SBT结束前5-10min,T4拔管

测量方法:

心电信号采集:采用床旁多功能监护仪通过设备的 Research Interface 科研 数据接口,以 ≥ 500 Hz 的采样率实时导出原始、高保真心电图波形数据。 分析软件:使用专业 HRV 分析软件 Kubios HRV,对导出的心电信号进行 后处理与分析。 时域指标: SDNN:全部正常窦性心搏(NN)间期的标准差,反映总体自主神经张力。 RMSSD:相邻 NN 间期差值均方的平

Measure time point of outcome:

T1 - 30-60 minutes before SBT; T2 - Early stage of SBT, 5-10 minutes; T3 - 5-10 minutes before the e

Measure method:

Electrocardiogram (ECG) acquisition: The bedside multifunctional monitor exports raw, high-resolution ECG waveforms in real time at a sampling rate of ≥500 Hz via the device's Research Interface. Analysis software: Professional HRV analysis software Kubios HRV is employed for post-processing and analysis of the exported ECG signals. Time-domain metrics: SDNN: Standard deviation of all normal sinusoidal heartbeats (NN) intervals, reflecting overall autonomic tension; RMSSD: Square root of the mea

指标中文名:

膈肌超声(DE、DTF、DCV)

指标类型:

次要指标

Outcome:

Diaphragmatic ultrasound (DE, DTF, DCV)

Type:

Secondary indicator

测量时间点:

T1-SBT前30-60min;T2-SBT早期5-10min;T3-SBT结束前5-10min,T4拔管后6h左右

测量方法:

B/M 模式图像 膈肌移动度: 于右侧肋缘下,利用 M 型超声测量平静呼吸时膈肌的垂直运动 幅度(单位:cm)。 膈肌增厚分数: 于腋前线第 8-10 肋间,利用 B 型超声测量膈肌在呼气末与吸 气末的厚度,并计算:DTF = (吸气末厚度 - 呼气末厚度) / 呼气末厚度 × 100%。 膈肌收缩速度: 基于上述 M 型影像,计算:DCV = 膈肌移动度 / 吸气时间(单 位:cm/s)。

Measure time point of outcome:

T1 - 30-60 minutes before SBT; T2 - Early stage of SBT, 5-10 minutes; T3 - 5-10 minutes before the e

Measure method:

B/M mode ultrasound images Diaphragm excursion: The vertical movement amplitude of the diaphragm (unit: cm) during quiet breathing is measured using M-mode ultrasound under the right subcostal margin. Diaphragmatic thickening fraction: The thickness of the diaphragm at end-expiration and end-inspiration is measured using B-mode ultrasound at the 8th to 10th intercostal spaces along the anterior axillary line, and calculated as: DTF = (end-inspiratory thickness ? end-expiratory thickness) / end-e

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

因伦理及隐私保护要求,暂不公开共享原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Researchers can contact PI to submit research proposals if they so desire, and analyses can be performed on a secure platform after approval by the Ethics Committee and signing of a data use agreement

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用纸质CRF与电子数据库(Excel)结合的方式进行管理。CRF模板作为研究原始文件留存备查

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Paper CRF and electronic database (Excel) are used to manage. The CRF template is kept for reference as the original document of the study

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-06-01 16:25:13